BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cushing's Syndrome readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Cushing's Syndrome\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03604198-399@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Relacorilant (Lifyorli): Phase 2 readout est. (NCT03604198)
DESCRIPTION:Relacorilant (Lifyorli)\, phase 2\, Cushing's Syndrome.\nStudy:
  Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant i
 n Patients With Cushing Syndrome\nEstimated primary completion: December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/relacorilant-lif
 yorli#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03604198
URL:https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
